WO1996012719A1 - Derive de quinoline - Google Patents
Derive de quinoline Download PDFInfo
- Publication number
- WO1996012719A1 WO1996012719A1 PCT/JP1995/002167 JP9502167W WO9612719A1 WO 1996012719 A1 WO1996012719 A1 WO 1996012719A1 JP 9502167 W JP9502167 W JP 9502167W WO 9612719 A1 WO9612719 A1 WO 9612719A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- carbon atoms
- quinolyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a quinoline derivative having a hypoglycemic effect.
- an insulin preparation as an injection or a sulfonyl urine such as a biguanide such as metformin hydrochloride and tolutamide as an oral preparation have been used.
- a biguanide such as metformin hydrochloride and tolutamide
- insulin preparations are cumbersome to use due to injections, while biguanides, which are orally administered, cause lactic acidosis, and sulfonylureas have the side effect of severe hypoglycemia.
- troglitazone trog li tazone: European Patent No.
- Troglitazone hydrochloride pioglitazone hydrochloride (pi og lit azon e), which has a new mechanism of action to improve dysfunction of insulin (insulin resistance) which does not have these disadvantages, has been developed.
- Hydrochloride European Patent No. 193,256 and the like, and 5-substituted benzylthiazolidine-1, 4-dione derivatives have attracted attention.
- Troglitazone has a hypoglycemic effect and a neutral flour fat-reducing effect, improves impaired insulin receptor function, also acts on glucose transporters and glucokinase, and impairs insulin action. It is said to improve.
- An object of the present invention is to provide a novel quinoline derivative having a hypoglycemic action.
- an object of the present invention is to provide a novel quinoline derivative having a hypoglycemic effect by oral administration.
- R 1 is hydrogen, an alkyl group having 1 to 6 carbon atoms, -NR 4 R s (R 4 and R 5 are each independently of one another, hydrogen, alkyl having 1 to 6 carbon atoms, phenyl, pyridyl, pyrimidyl, Or a benzoyl) amino group, or as a substituent, alkyl having 1 to 6 carbons, alkoxy having 1 to 6 carbons, halogen, hydroxy, halogenoalkyl having 1 to 6 carbons, or 1 to 6 carbons
- R 2 is hydrogen, an alkyl group having 1 to 6 carbon atoms, -NR 6 ′ R 7 (R 6 and R 7 are independently of each other, hydrogen, alkyl having 1 to 6 carbon atoms, phenyl, pyridyl, pyrimidyl Or a benzoyl) amino group, or a C1-C6 alkyl, a C1-C6 alkoxy, a halogen, a hydroxy, a C1-C6 halogenoalkyl, a C1-carbon A phenyl group, a naphthyl group, a cycloalkyl group having 3 to 8 carbon atoms, or a ring-forming atom, which may have a halogenoalkoxy, nitro, amino, phenyl, phenyl, phenyl, thiazolyl, or pyridyl group Represents a 5- to 8-membered complex group consisting of 1 to 2 nitrogen, oxygen, or sulfur
- the quinoline derivative represented by the formula is preferred.
- the quinoline derivative of the present invention includes the following general formula (m):
- R 3 is a substituent having 1 to 6 carbon atoms, alkyl having 1 to 6 carbon atoms, halogen, hydroxy, halogenoalkyl having 1 to 6 carbon atoms, halogenoalkoxy having 1 to 6 carbon atoms, nitro, A phenyl, oxazolyl, or pyridyl group which may have an amino, phenyl, phenyl, thienyl, furyl, thiazolyl or pyridyl group, and k represents an integer of 0-4.
- the quinoline derivative represented by is preferred.
- C1-C6 alkyl groups eg, methyl, ethyl, propyl, and isobutyl
- R 5 or —NR e R 7 R 4 , R 5 , R 6 , and R 7 may be the same or different from each other. It is selected from hydrogen, alkyl having 1 to 6 carbon atoms (eg, methyl, ethyl, propyl, and isopropyl), phenyl, pyridyl, pyrimidyl, or benzoyl. In addition, these alkyl, phenyl, pyridyl, pyrimidyl, and benzoyl may have a substituent.
- Phenyl, naphthyl, cycloalkyl group having 3 to 8 carbon atoms eg, cyclohexyl, cyclopentyl
- ⁇ -forming atom consisting of 1 to 2 nitrogen, oxygen, or sulfur and the remaining number of carbon atoms 5- to 8-membered heterocyclic groups (eg, pyridyl, thiazolyl, oxazolyl, chenyl, furyl, pyrrolyl, morpholinyl, indolyl, imidazolyl, biberidinyl).
- all of these phenyl, naphthyl, cycloalkyl and heterocyclic groups have 1 or 2 or more alkyl having 1 to 6 carbons as substituents (eg, methyl, ethyl, brovir, and Isopropyl) “alkoxy having 1 to 6 carbon atoms (eg, methoxy, ethoxy, and propoxy, isopropoxy), halogen (eg, chlorine, fluorine, bromine), hydroxy, halogenoalkyl having 1 to 6 carbon atoms (eg, 2 —Chloroethyl, trifluoromethyl), halogenoalkoxy with 1 to 6 carbon atoms (eg, 2 —chloroethoxy), nitro, amino (eg, NH 2 , methylamino, methylamino, dimethylamino, getylamino), phenyl, chenyl, frill , Thiazolyl, or pyridyl may also be
- Phenyl, oxazolyl, pyridyl is, as a substituent, 1 or 2 or more alkyl having 1 to 6 carbons (eg, methyl, ethyl, propyl, and isopropyl), and alkoxy having 1 to 6 carbons (eg, Methoxy, ethoxy, and propoxy, isobroboxy), halogen (eg, chlorine, fluorine, bromine), hydroxy, halogenoalkyl having 1 to 6 carbon atoms (eg, 2-chloroethyl, trifluoromethyl), 1 to 1 carbon atoms 6 may have a halogenoalkoxy (eg, 2-chloro ethoxy), nitro, amino (eg, NH 2 , methylamino, ethylamino, dimethylamino, getylamino), phenyl,
- alkyl having 1 to 6 carbons eg, methyl, ethyl, propyl,
- S sulfur or 0 (oxygen).
- oxygen preferably it is S.
- P and q are preferably 0. m, n, and k are preferably 1 or 2.
- the quinoline ring is also substituted with an alkyl having 1 to 6 carbon atoms such as methyl, ethyl and butyl, and an alkoxy having 1 to 6 carbon atoms such as methoxy and ethoxy. It may have a substituent such as halogen such as chlorine and fluorine.
- a group bonded to the pyridine ⁇ moiety of quinoline ⁇ such as thiazolidine-1,2,4-dione-15-ylmethyl, and R 1 — (CH 2 ) Pyridine groups attached to benzene ring portion of the ring, such as m one Z- (CH 2) p scratch, as seen in the general formula (m), respectively 3-position of the reluctant down ring, 7 It is preferable to bond at the position.
- the quinoline derivative of the present invention may exist as a pharmacologically acceptable salt.
- a salt include an acid salt with an organic or inorganic acid such as hydrochloric acid or acetic acid, or an alkali metal (eg, , Sodium and potassium) and the like.
- an asymmetric carbon is present at the 5-position of the thiazolidine-1,2,4-dione ring of the quinoline derivative of the present invention, the quinoline derivative of the present invention includes an optically active compound, Racemic compounds are also included.
- the quinoline derivative represented by the above general formula (m) of the present invention can be obtained by, for example, the following production method (synthesis method 11).
- 3-nitro-7-hydroxyquinoline of the formula (a) is used for the reaction of dimethylformamide (DMF), benzene, toluene, dichloromethane, pyridine, tetrahydrofuran (THF), dimethylsulfoxide (DMSO), etc.
- a halogen compound of the formula (b) is reacted in the presence of a base such as sodium hydride, sodium alkoxide, triethylamine, sodium hydroxide, sodium carbonate, etc. —Ditroquinoline derivative power is obtained.
- the 3-ditroquinoline derivative of the formula (c) is catalytically reduced using platinum oxide, palladium carbon, or the like in a solvent that does not participate in a reaction such as ethanol, ethyl acetate, methanol, or THF, or iron or zinc and acetic acid.
- a solvent that does not participate in a reaction such as ethanol, ethyl acetate, methanol, or THF, or iron or zinc and acetic acid.
- reduction using tin chloride (II) is performed to obtain the 3-aminoquinoline derivative of formula (d).
- the 3-aminoquinoline derivative of the formula (d) is reacted with sodium nitrite in a solvent that does not participate in the reaction of acetone, methanol, or the like, in the presence of a hydrohalic acid such as aqueous hydrogen sulfide or concentrated hydrochloric acid.
- a hydrohalic acid such as aqueous hydrogen sulfide or concentrated hydrochloric acid.
- the 2-halogeno-3-quinolyl brobionate of the formula (e) is converted to a solvent such as ethanol, 2-methoxyethanol, methanol, propanol, or isopropanol which does not participate in the reaction in the presence of sodium acetate.
- a solvent such as ethanol, 2-methoxyethanol, methanol, propanol, or isopropanol which does not participate in the reaction in the presence of sodium acetate.
- thiourea to give a 2-iminothiazolidine-14-one derivative of formula (f).
- a 2-iminothiazolidine-14-one derivative of the formula (f) is used, for example, in a mixed solution of an inorganic acid and an alcohol (examples of inorganic acids: hydrochloric acid, sulfuric acid, hydrogen bromide, examples of alcohol: ethanol) , Methanol, propanol and isopropanol) to obtain a quinoline derivative of the general formula (ffl).
- the quinoline derivative represented by the general formula (m) can also be obtained by the following production method (synthesis method 1).
- G represents a leaving group such as chlorine, bromine, iodine, mesyloxy, trisyloxy, etc.
- M represents an alkali metal such as lithium, sodium, potassium, etc.
- R 3 and n are the same as those described above. Meaningful
- the quinoline derivative represented by the general formula (m) can also be obtained by the following production method (synthesis method-3).
- the 3-formylquinoline derivative is dehydrated and condensed with thiazolidin-1,2,4-dione in the presence of a base such as biveridine, piperazine, triethylamine, and soda carbonate using the synthesis method 13.
- a base such as biveridine, piperazine, triethylamine, and soda carbonate
- a quinoline derivative represented by the general formula (() thiazolidine-1-5-indene type
- a quinoline derivative represented by the general formula ( ⁇ ) can be obtained. .
- the quinoline derivative represented by the general formula (ffl) can also be obtained by the following production method (synthesis method 14).
- a 7-hydric xyquinoline derivative and, for example, benzyl alcohol (R 3 — (CH 2 ) ⁇ -OH) were mixed with THF as a solvent and triphenylphenylphosphine (PPh
- the quinoline derivative of the general formula (ffl) can be obtained by treating with 3 ) and acetyl dicarboxylate (DEAD) (Mitsunobu reaction).
- KK Ay mice a model animal of inulin-independent diabetes.
- KK Ay mice (9-11 weeks old) were divided into homogeneous groups according to plasma glucose concentration, and then suspended in a 1% methylcellulose solution (the quinoline derivative synthesized in each Example described below) and Bioglitazone (comparative compound) was orally administered once a day for 3 days.
- a 1% methylcellulose solution was orally administered to the control (drug-free group). Blood was collected 18 hours after the last administration, and the plasma glucose concentration was measured.
- the measurement was performed by an automatic analyzer (Type 705, manufactured by Hitachi, Ltd.) by an enzyme method using Autocera GLU (Daiichi Pure Chemicals Co., Ltd.).
- the plasma glucose concentration of each compound administration group was determined, and the ratio (percent) of the value to the control was calculated. The results are shown in Table 1.
- test compound was suspended in a 1% aqueous solution of methylcellulose, and the suspension was fed with a CRF-solid sample (manufactured by Oriental Yeast Co., Ltd.) and water freely.
- Cr j CD (Sprague-Dawley) system rat ( Female, 5 weeks old, 5 animals per group) 1 daily Gavage over 4 weeks.
- the dose of the test compound was SOOmgZkg gZ day and 600mg / kgZ day for the compound of the present invention (Example 6), and 200mgZkgZ day for bioglitazone (bioglitazone hydrochloride: comparative compound).
- the quinoline derivative of the present invention can be administered either orally or parenterally.
- Oral dosage forms include tablets, capsules, powders, granules and scillos.
- Parenteral administration methods include mucosal administration such as eye drops, inhalants, propellants, suppositories, etc. Examples include body surface administration of ointments and the like, and intravascular and tissue administration of injections and the like.
- the above oral preparations are produced using ordinary excipients, disintegrants, binders, lubricants, pigments, diluents and the like.
- Excipients include glucose and lactose; disintegrants include hard powder, calcium carboxymethylcellulose; lubricating agents include magnesium stearate, talc; and binding agents include hydroxypropyl cellulose.
- disintegrants include hard powder, calcium carboxymethylcellulose; lubricating agents include magnesium stearate, talc; and binding agents include hydroxypropyl cellulose.
- lubricating agents include magnesium stearate, talc; and binding agents include hydroxypropyl cellulose.
- binding agents include hydroxypropyl cellulose.
- Gelatin, polyvinylpyrrolidone and the like are used.
- parenteral preparations and injections they are prepared using distilled water for injection, physiological saline, and Ringer's solution.
- the dosage of the quinoline derivative of the present invention is usually about 0.1 mg to 200 mg per day for injection and about 1 mg to 200 mg per day for oral administration for adults. It can be increased or decreased depending on species, symptoms, etc.
- the quinoline derivative of the present invention has an excellent hypoglycemic effect and is low in toxicity, so that it is useful as a therapeutic agent for diabetes, particularly for oral administration.
- 3-Amino-7- (2-trifluoromethylbenzyloxy) quinoline (60 Omg, 1.9 mmol) is dissolved in a mixed solvent of acetone and methanol (1.76 mLZ 4.46 mL), and 47% hydrogen bromide is dissolved. Water (1.35 g) was added.
- the ®® was separated, washed with water, and washed with sodium sulfate! ⁇ .
- the solvent was distilled off under reduced pressure to give 300 mg of the title compound as a crude product in the residue.
- the crude product was used in the next step without purification of [il ⁇ ].
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/809,592 US5693651A (en) | 1994-10-20 | 1995-10-20 | Quinoline derivatives |
KR1019970702575A KR100356551B1 (ko) | 1994-10-20 | 1995-10-20 | 퀴놀린유도체 |
AU37098/95A AU712802B2 (en) | 1994-10-20 | 1995-10-20 | Quinoline derivatives |
EP95934864A EP0787725B1 (en) | 1994-10-20 | 1995-10-20 | Quinoline derivative |
DE69530501T DE69530501D1 (de) | 1994-10-20 | 1995-10-20 | Chinolinderivat |
RU97107992/04A RU2137770C1 (ru) | 1994-10-20 | 1995-10-20 | Производные хинолина |
AT95934864T ATE238297T1 (de) | 1994-10-20 | 1995-10-20 | Chinolinderivat |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28130194 | 1994-10-20 | ||
JP6/281301 | 1994-10-20 | ||
JP21805695 | 1995-08-03 | ||
JP7/218056 | 1995-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996012719A1 true WO1996012719A1 (fr) | 1996-05-02 |
Family
ID=26522365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/002167 WO1996012719A1 (fr) | 1994-10-20 | 1995-10-20 | Derive de quinoline |
Country Status (10)
Country | Link |
---|---|
US (1) | US5693651A (ja) |
EP (1) | EP0787725B1 (ja) |
KR (1) | KR100356551B1 (ja) |
CN (1) | CN1071333C (ja) |
AT (1) | ATE238297T1 (ja) |
AU (1) | AU712802B2 (ja) |
CA (1) | CA2201113A1 (ja) |
DE (1) | DE69530501D1 (ja) |
RU (1) | RU2137770C1 (ja) |
WO (1) | WO1996012719A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020871A1 (fr) * | 1996-11-08 | 1998-05-22 | Nippon Chemiphar Co., Ltd. | Agent diminuant la graisse viscerale |
WO2004074284A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Oxazole-derivatives as ppar agonists |
JP2010511608A (ja) * | 2006-11-30 | 2010-04-15 | ダウ アグロサイエンシィズ エルエルシー | 2−置換−5−(1−アルキルチオ)アルキルピリミジンの製造方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073273A1 (fr) * | 1999-05-28 | 2000-12-07 | Nippon Chemiphar Co., Ltd. | Procede d'obtention de derives 2-halo-3-(3-quinolyl) acide proprionique |
EP1354602B1 (en) * | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
US7015345B2 (en) * | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
US20050119314A1 (en) * | 2002-04-05 | 2005-06-02 | Sankyo Company, Limited | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
EP2516425B1 (en) | 2009-12-23 | 2015-09-02 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
CA2832865C (en) | 2011-04-22 | 2021-05-11 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61267580A (ja) * | 1985-01-19 | 1986-11-27 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ248573A (en) * | 1992-09-10 | 1996-02-27 | Lilly Co Eli | 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions |
FR2696743B1 (fr) * | 1992-10-12 | 1994-12-23 | Adir | Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
-
1995
- 1995-10-20 WO PCT/JP1995/002167 patent/WO1996012719A1/ja active IP Right Grant
- 1995-10-20 AT AT95934864T patent/ATE238297T1/de not_active IP Right Cessation
- 1995-10-20 US US08/809,592 patent/US5693651A/en not_active Expired - Fee Related
- 1995-10-20 CA CA002201113A patent/CA2201113A1/en not_active Abandoned
- 1995-10-20 KR KR1019970702575A patent/KR100356551B1/ko not_active IP Right Cessation
- 1995-10-20 CN CN95196871A patent/CN1071333C/zh not_active Expired - Fee Related
- 1995-10-20 AU AU37098/95A patent/AU712802B2/en not_active Ceased
- 1995-10-20 RU RU97107992/04A patent/RU2137770C1/ru not_active IP Right Cessation
- 1995-10-20 EP EP95934864A patent/EP0787725B1/en not_active Expired - Lifetime
- 1995-10-20 DE DE69530501T patent/DE69530501D1/de not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61267580A (ja) * | 1985-01-19 | 1986-11-27 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020871A1 (fr) * | 1996-11-08 | 1998-05-22 | Nippon Chemiphar Co., Ltd. | Agent diminuant la graisse viscerale |
US6121288A (en) * | 1996-11-08 | 2000-09-19 | Nippon Chemiphar Co., Ltd. | Visceral fat lowering agent |
WO2004074284A1 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Oxazole-derivatives as ppar agonists |
JP2010511608A (ja) * | 2006-11-30 | 2010-04-15 | ダウ アグロサイエンシィズ エルエルシー | 2−置換−5−(1−アルキルチオ)アルキルピリミジンの製造方法 |
JP2013056912A (ja) * | 2006-11-30 | 2013-03-28 | Dow Agrosciences Llc | 2−置換−5−(1−アルキルチオ)アルキルピリミジンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US5693651A (en) | 1997-12-02 |
KR100356551B1 (ko) | 2002-12-18 |
CA2201113A1 (en) | 1996-05-02 |
ATE238297T1 (de) | 2003-05-15 |
EP0787725B1 (en) | 2003-04-23 |
KR970707122A (ko) | 1997-12-01 |
DE69530501D1 (de) | 2003-05-28 |
AU712802B2 (en) | 1999-11-18 |
EP0787725A1 (en) | 1997-08-06 |
CN1170411A (zh) | 1998-01-14 |
AU3709895A (en) | 1996-05-15 |
EP0787725A4 (en) | 1998-01-07 |
CN1071333C (zh) | 2001-09-19 |
RU2137770C1 (ru) | 1999-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2061695C1 (ru) | Способ получения арилпиперазинил-гетероциклических соединений или их фармацевтически приемлемой кислотно-аддитивной соли | |
WO2021018023A1 (zh) | 小分子glp-1受体调节剂 | |
CA2459224C (en) | 1,3-benzothiazinone derivatives and the use thereof | |
CA2163028C (en) | New thiazolidinediones and pharmaceutical agents containing them | |
CA2193171A1 (en) | Thiazolidinedione derivatives, method for preparing the derivatives and pharmaceutical compositions containing same | |
WO1996012719A1 (fr) | Derive de quinoline | |
WO2022202864A1 (ja) | 縮合環を有するglp-1受容体作動薬を含有する医薬組成物 | |
KR20100092909A (ko) | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
JPH02142787A (ja) | 新規化合物,その製法及びそれを含む医薬組成物 | |
AU5208299A (en) | Novel angiogenesis inhibitors | |
FR2530626A1 (fr) | Composes de carbostyryle | |
KR100340615B1 (ko) | 피리딘고리로치환된티아졸리딘및옥사졸리딘및혈당감소제로서의그의용도 | |
WO2007143597A2 (en) | Organic compounds | |
JPH0912575A (ja) | ベンゾオキサジンおよびベンゾチアジン誘導体 | |
CN109134463B (zh) | β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途 | |
KR20010052235A (ko) | 인돌 유도체 | |
WO2008053863A1 (fr) | Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one | |
JPH10237049A (ja) | ベンズイソキサゾ−ル誘導体 | |
CN111727186B (zh) | 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途 | |
FR2595701A1 (fr) | Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant | |
KR920003927B1 (ko) | 헤테로사이클릭구아니딘 5ht_3 길항물질 | |
FR2761071A1 (fr) | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique | |
EP0771319A1 (en) | Tricyclic compounds, their production and use | |
NZ323967A (en) | 4,9-Dihydro-4,9-dioxo-2-substituted-1H-naphtho[2,3]imidazole derivatives and their use in treating circulatory disorders | |
WO1996035688A1 (fr) | Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95196871.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995934864 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2201113 Country of ref document: CA Ref document number: 2201113 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08809592 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970702575 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1995934864 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970702575 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970702575 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995934864 Country of ref document: EP |